Cancer of the Ovary, Fallopian Tube, and Peritoneum: 2021 Update

Overview

Journal Int J Gynaecol Obstet

Publisher Wiley

Specialty Gynecology & Obstetrics

Date 2021 Oct 20

PMID 34669199

Citations 139

Authors

Jonathan S Berek

Malte Renz

Sean Kehoe

Lalit Kumar

Michael Friedlander

Affiliations

Soon will be listed here.

Abstract

In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high-grade serous carcinomas (HGSC). Stage IC is now divided into three categories: IC1 (surgical spill); IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface); and IC3 (malignant cells in the ascites or peritoneal washings). The updated staging includes a revision of Stage IIIC based on spread to the retroperitoneal lymph nodes alone without intraperitoneal dissemination. This category is now subdivided into IIIA1(i) (metastasis ≤10 mm in greatest dimension), and IIIA1(ii) (metastasis >10 mm in greatest dimension). Stage IIIA2 is now "microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph node" metastasis. This review summarizes the genetics, surgical management, chemotherapy, and targeted therapies for epithelial cancers, and the treatment of ovarian germ cell and stromal malignancies.

Citing Articles

Upregulated FSP1 by GPD1/1L mediated lipid droplet accumulation enhances ferroptosis resistance and peritoneal metastasis in gastric cancer.

Lin G, Liu Q, Xie C, Ding K, Mo G, Zeng L Cell Commun Signal. 2025; 23(1):132.

PMID: 40075460 PMC: 11899195. DOI: 10.1186/s12964-025-02126-x.

An Assessment of the Effectiveness of Preoperative İmaging Modalities (MRI, CT, and 18F-FDG PET/CT) in Determining the Extent of Disease Spread in Epithelial Ovarian-Tubal-Peritoneal Cancer (EOC).

Kandemir H, Sozen H, Kartal M, Ozkan Z, Topuz S, Salihoglu M Medicina (Kaunas). 2025; 61(2).

PMID: 40005316 PMC: 11857206. DOI: 10.3390/medicina61020199.

Intra-Tumoral Lymphocytic Infiltration Is Associated with Favorable Prognosis in Suboptimal Surgery in High-Grade Serous Ovarian Carcinoma.

Harada H, Hachisuga T, Harada Y, Shibahara M, Murakami M, Nuratdinova F Diagnostics (Basel). 2025; 15(4).

PMID: 40002574 PMC: 11854212. DOI: 10.3390/diagnostics15040422.

Prognostic Significance of S100A4 in Ovarian Clear Cell Carcinoma: Its Relation to Tumor Progression and Chemoresistance.

Hayashi M, Yokoi A, Nakagawa M, Hashimura M, Oguri Y, Saegusa M Cancers (Basel). 2025; 17(2).

PMID: 39857966 PMC: 11763377. DOI: 10.3390/cancers17020184.

Prognostic significance of right subdiaphragmatic washing cytology in patients with endometrial cancer.

Yokoyama T, Okame S, Okazawa-Sakai M, Fujimoto E, Hibino Y, Teramoto N Sci Rep. 2025; 15(1):2365.

PMID: 39825040 PMC: 11742401. DOI: 10.1038/s41598-025-86784-4.

References

Zanetta G, Rota S, Chiari S, Bonazzi C, BRATINA G, Mangioni C . Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol. 2001; 19(10):2658-64. DOI: 10.1200/JCO.2001.19.10.2658. View

Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E . Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol. 2011; 29(27):3628-35. DOI: 10.1200/JCO.2010.33.8566. View

Bookman M, Brady M, McGuire W, Harper P, Alberts D, Friedlander M . Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009; 27(9):1419-25. PMC: 2668552. DOI: 10.1200/JCO.2008.19.1684. View

Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M . Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012; 107(4):588-91. PMC: 3419956. DOI: 10.1038/bjc.2012.307. View

Rose P, Blessing J, Soper J, Barter J . Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 1998; 70(2):267-71. DOI: 10.1006/gyno.1998.5080. View

Buys S, Partridge E, Black A, Johnson C, Lamerato L, Isaacs C . Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011; 305(22):2295-303. DOI: 10.1001/jama.2011.766. View

Brown J, Brady W, Schink J, Van Le L, Leitao M, Yamada S . Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer. 2013; 120(3):344-51. PMC: 4250045. DOI: 10.1002/cncr.28421. View

Nagle C, Francis J, Nelson A, Zorbas H, Luxford K, Fazio A . Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2011; 29(16):2253-8. DOI: 10.1200/JCO.2010.32.2164. View

Homesley H, Bundy B, Hurteau J, Roth L . Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. Gynecol Oncol. 1999; 72(2):131-7. DOI: 10.1006/gyno.1998.5304. View

10.

Kehoe S, Hook J, Nankivell M, Jayson G, Kitchener H, Lopes T . Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015; 386(9990):249-57. DOI: 10.1016/S0140-6736(14)62223-6. View

11.

Gershenson D, Sun C, Iyer R, Malpica A, Kavanagh J, Bodurka D . Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2012; 125(3):661-6. PMC: 4405157. DOI: 10.1016/j.ygyno.2012.02.037. View

12.

Schumer S, Cannistra S . Granulosa cell tumor of the ovary. J Clin Oncol. 2003; 21(6):1180-9. DOI: 10.1200/JCO.2003.10.019. View

13.

Berek J, Renz M, Kehoe S, Kumar L, Friedlander M . Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021; 155 Suppl 1:61-85. PMC: 9298325. DOI: 10.1002/ijgo.13878. View

14.

van der Burg M, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G . The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995; 332(10):629-34. DOI: 10.1056/NEJM199503093321002. View

15.

Pfisterer J, Ledermann J . Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol. 2006; 33(2 Suppl 6):S12-6. DOI: 10.1053/j.seminoncol.2006.03.012. View

16.

Vasey P, Jayson G, Gordon A, Gabra H, Coleman R, Atkinson R . Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004; 96(22):1682-91. DOI: 10.1093/jnci/djh323. View

17.

Gilbert L, Basso O, Sampalis J, Karp I, Martins C, Feng J . Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol. 2012; 13(3):285-91. DOI: 10.1016/S1470-2045(11)70333-3. View

18.

Fagotti A, Ferrandina M, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V . Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020; 30(11):1657-1664. DOI: 10.1136/ijgc-2020-001640. View

19.

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G . Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014; 32(13):1302-8. DOI: 10.1200/JCO.2013.51.4489. View

20.

Monk B, Herzog T, Kaye S, Krasner C, Vermorken J, Muggia F . Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010; 28(19):3107-14. DOI: 10.1200/JCO.2009.25.4037. View